DefiniGEN

About

pixlbio is a biotechnology company based in Cambridge, UK, with operations in Sweden. It specializes in predictive biology using induced pluripotent stem cell (iPSC)-derived human cellular models, high-throughput imaging, and AI-powered phenomics. The company was formed from the merger of DefiniGEN and Phenaros and focuses on drug discovery and safety testing through advanced automation and analytics. The company offers an integrated platform that includes various iPSC-derived models, such as hepatocytes and intestinal organoids, along with proprietary robotics for experimental setup and quality control. Its AI-driven analytics provide insights into drug responses and toxicities, enhancing reproducibility and accelerating drug development. With a team of 11-50 employees, pixlbio is ISO 9001:2015 certified and has received a Gold Award for its contributions to biotechnology research. The company collaborates with leading pharmaceutical firms and research institutions, including AstraZeneca and Sanofi, to deliver high-quality predictive models and support scalable experimentation.